Elekta: Revolutionary Treatment Option Offers New Hope to Russian Cancer Patients

Regulatory News:

Elekta (STO:EKTAB):

Two of Russia’s leading research centers, The Meshalkin Research Institute of Circulation Pathology (NRIBCP, Novosibirsk, Russia) and the Hertzen Moscow Oncology Research Institute (MORI, Moscow, Russia), have purchased Elekta Axesse™ systems which will, for the first time in Russia, allow clinicians to treat cancer tumors throughout the body with ultra-high precision while minimizing damage to surrounding healthy tissue.

"Elekta Axesse will help us to build the one of the most advanced cancer centers in Russia,” says Professor Alexander M. Karaskov, Director of the Meshalkin Research Institute. "The system combines speed and accuracy with the ability to target tumors throughout the body.”

Elekta Axesse will be delivered with the latest technology, Elekta VMAT (Volumetric Modulated Arc Therapy), which enables faster treatment time and more accurate targeting of the dose. Hertzen MORI will be the first clinic in Russia to provide this technology to patients.

"The system will enable us to attain very-high precision and accuracy for every patient, in many cases sub-millimeter. This is specifically important in treatment of difficult sites such as lung or liver,” commented Professor Anna Boyko from MORI. "The advanced 3D imaging capabilities of Elekta Axesse facilitate rapid, precise targeting of tumors, and the highly-conformal radiation delivery system effectively treats tumors while minimizing damage to a patient’s healthy tissue.”

This advanced technology is delivered with MOSAIQ®, the most advanced integrated suite of Electronic Medical Record (EMR) software in oncology; which enhances workflow, improves productivity and simplifies medical record accessibility throughout the department.

"Software support for efficient workflow is a key component in a treatment system and MOSAIQ, along with the entire software package supplied by Elekta, is second to none. In a clinical setting, the system manages documents, patient and user schedules and imports treatment plans into the EMR as well as verifies and records the treatment delivered, all handled from one integrated user environment. This definitely helps to streamline clinicians’ workflow, ultimately saving precious time,” says Dr. Olga Efimova, NRIBCP’s Head of Radiosurgery.

Generally, on the opinion of Professor Andrey Chernichenko, President of the Russian Association of the Therapeutic Radiation Oncologist (RATRO), "such sophisticated equipment will open new era for all Russian oncology – high precision, super effective irradiation for many ‘social important’ tumors.”

Notes to editors

Cancer is the third largest cause of death in Russia. The World Health Organization estimates that it will rise to the second largest cause, following cardiovascular disease, by 2030.(1)

About Meshalkin Research Institute

The Meshalkin Research Institute is based in Novosibirsk in Russia’s Siberian region. It has an extensive history in medical advancement and scientific discovery, holding over 250 internationally-recognized certificates and patents. The Institute works consistently with the Russian Academy of Science and the Russian Academy of Medical Science in order to drive innovation in medical research and treatment.

About Hertzen Moscow Oncology Research Institute

The Hertzen clinic is one of the leading cancer clinics in Russia and also one of the oldest in Europe. The institute offers a wide range of solutions to treat cancer. Including linear accelerators and brachy therapy.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.

References

1. World Health Organization. The Impact of Cancer In Your Country - Graphs: Russian Federation. Available at: http://www.who.int/infobase/report.aspx?iso=RUS&rid=119&goButton=Go.

This information was brought to you by Cision http://www.cisionwire.com